Valuation: EyePoint, Inc.

Market Cap 1.17B 1.01B 947M 864M 1.62B 111B 1.65B 11.14B 4.35B 55.71B 4.38B 4.28B 186B P/E 2026 *
-3.54x
P/E 2027 * -4.53x
Enterprise Value 844M 731M 685M 625M 1.17B 80.47B 1.19B 8.05B 3.15B 40.29B 3.17B 3.1B 134B EV / Sales 2026 *
481x
EV / Sales 2027 * 36.7x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day+3.68%
1 week+10.45%
Current month+10.45%
1 month-8.08%
3 months-0.66%
6 months+4.00%
Current year-25.94%
1 week 12.37
Extreme 12.37
14.32
1 month 11.54
Extreme 11.54
14.58
Current year 11.3
Extreme 11.295
18.87
1 year 9.65
Extreme 9.65
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
41.5
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap.
7/10/26 A Fiscal year

Chief Executive Officer

41,393 0.0494%
6/30/26 A Fiscal year

Chief Technology Officer

14,625 0.0174%
3/23/26 A Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+3.68%+10.45%+25.86%-4.72% 1.13B
+0.43%+4.31%+90.84%+130.99% 1,083B
+0.41%+1.27%+50.98%+50.05% 626B
-0.53%+1.04%+25.23%+63.46% 442B
-0.92%+0.22%+48.34%+37.85% 363B
-1.32%-0.21%+29.07%+36.81% 295B
-1.20%-2.78%+5.56%+6.09% 248B
+0.45%+2.05%+46.04%+58.54% 224B
-2.51%+1.77%-6.55%-51.74% 210B
+0.07%+3.12%+13.21%+69.84% 168B
Average -0.14%+2.41%+32.86%+39.72% 366.02B
Weighted average by Cap. -0.26%+2.20%+49.21%+65.94%

Financials

2026 *2027 *
Net sales 1.75M 1.52M 1.42M 1.3M 2.44M 167M 2.48M 16.75M 6.55M 83.81M 6.59M 6.45M 279M 21.92M 18.99M 17.79M 16.23M 30.51M 2.09B 30.98M 209M 81.8M 1.05B 82.29M 80.5M 3.49B
Net income -344M -298M -279M -255M -479M -32.81B -486M -3.28B -1.28B -16.43B -1.29B -1.26B -54.78B -289M -251M -235M -214M -403M -27.61B -409M -2.76B -1.08B -13.83B -1.09B -1.06B -46.1B
Net Debt -323M -280M -262M -239M -449M -30.79B -456M -3.08B -1.2B -15.42B -1.21B -1.19B -51.4B -362M -314M -294M -268M -504M -34.52B -512M -3.46B -1.35B -17.29B -1.36B -1.33B -57.64B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
12/08/26 $13.53 +3.68% 2,259,472
11/08/26 $13.05 -0.15% 2,058,473
10/08/26 $13.07 -5.90% 1,757,173
07/08/26 $13.89 +8.26% 1,655,696
06/08/26 $12.83 +4.73% 2,240,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
13.53USD
Average target price
40.93USD
Spread / Average Target
+202.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock